Barbara Pro

Barbara Pro

Auto-generated profile, based on publicly available information

Barbara Pro

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2009 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
GFG. S. Falchook
G. S. Falchook
FVFrancisco Vega
Francisco Vega
NDN. H. Dang
N. H. Dang
FSF. Samaniego
F. Samaniego
MRM. A. Rodriguez
M. A. Rodriguez
BPB. Pro
B. Pro
Background: Hepatosplenic T-cell lymphoma (HSTCL) is a rare peripheral T-cell lymphoma; treatment with standard anthracycline-containing chemotherapy regimens has been disappointing, and an optimal treatment strategy for this patient population has not yet been determined. Methods: We identified 15 cases of pathologically confirmed HSTCL in the institution's database. Clinical characteristics and treatment results were reviewed. Results: Complete responses (CRs) were achieved in 7 of 14 patients who received chemotherapy. Achievement of CR was followed by hematopoietic stem-cell transplantation in three patients. Median duration of CR was 8 months (range 2 to 32+ months) with four patients currently alive and in CR at 5, 8, 12, and 32 months, respectively. Median overall survival (OS) was 11 months (range 2 to 36+ months). Patients who achieved a CR had a median OS of 13 months, compared with 7.5 months in patients who did not achieve a CR. Risk factors associated with worse outcome included male gender, failure to achieve a CR, history of immunocompromise, and absence of a T-cell receptor gene rearrangement in the gamma chain. Conclusion: A better understanding of the pathophysiology of HSTCL and new therapeutic strategies are needed.

20 March 2007 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
ASAndres O. Soriano
Andres O. Soriano
MTMichael A. Thompson
Michael A. Thompson
JAJoan H. Admirand
Joan H. Admirand
LFLuis E. Fayad
Luis E. Fayad
ARAlma M. Rodriguez
Alma M. Rodriguez
BPBarbara Pro
Barbara Pro

14 October 2008 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
BPBarbara Pro
Barbara Pro
BLBrian Leber
Brian Leber
MSMitchell Smith
Mitchell Smith
LFLuis Fayad
Luis Fayad
JRJorge Romaguera
Jorge Romaguera
AYAnas Younes
Anas Younes

15 February 2006 in Blood
Verified
Journal Article
Closed access
PDF file
AYAnas Younes
Anas Younes
BPBarbara Pro
Barbara Pro
LFLuis Fayad
Luis Fayad

9 February 2004 in Cancer
Verified
Journal Article
Open access
PDF file
BPBarbara Pro
Barbara Pro
AYAnas Younes
Anas Younes
MAMaher Albitar
Maher Albitar
NDNam H. Dang
Nam H. Dang
FSFelipe Samaniego
Felipe Samaniego
FCFernando Cabanillas
Fernando Cabanillas
BACKGROUND: Thalidomide has significant clinical activity in patients with multiple myeloma. However, its activity against other lymphoid tumors is unknown. The authors reported their experience with thalidomide in patients with recurrent/refractory non‐Hodgkin lymphoma and in patients with Hodgkin disease.METHODS: Nineteen patients (median age, 62 years) who had undergone a median of 5 previous treatment regimens were treated with escalating doses of thalidomide (200–800 mg per day) until disease progression or prohibitive toxicity was observed. The authors measured serum levels of angiogenesis factors before and after treatment.RESULTS: One patient (5%) with evidence of recurrent gastric mucosa—associated lymphoid tissue lymphoma achieved a complete response, and 3 patients (16%) achieved stable disease.CONCLUSIONS: The current study suggests that thalidomide has limited single‐agent activity in heavily pretreated patients with recurrent or refractory lymphoma. Cancer 2004. © 2004 American Cancer Society.

26 April 2011 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
MFMichelle Fanale
Michelle Fanale
LFLuis Fayad
Luis Fayad
BPBarbara Pro
Barbara Pro
FSFelipe Samaniego
Felipe Samaniego
MLMary Joy Liboon
Mary Joy Liboon
AYAnas Younes
Anas Younes